Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and calls has predictably returned. To cope, yes, we are quaffing cups of stimulation — our flavor at the moment is mocha nut fudge — and invite you to join us. And why not? The neurons can use all the help they can get. Meanwhile, here are a few tidbits to help you on your journey. Hope your day is successful and please do keep in touch. …
Many of the nation’s largest drug makers and distributors failed to implement even the most basic systems to halt suspicious drug orders as the opioid epidemic came into sharp focus, The Wall Street Journal writes, citing a court filing. The motion by lawyers for two Ohio counties alleges companies failed to analyze potentially suspicious orders until after they had shipped, applied rudimentary controls on excessive sales that were easy for bad actors to game, and handed the job of halting shady orders to sales departments incentivized to keep pills moving.
About the Author Reprints
Concerning Amgen and Allergan – when the first interest in biosimilar came 10 years ago, it was disheartening to many that 50% savings were “totally unrealistic.” The projected savings would be 30 pct, which would still be a savings against the much higher costs. Now 15% is being touted – what will come next, a target of price parity with the branded biologics?